


**Product Name** : CX-5461  
**Cat. No.** : PC-43493  
**CAS No.** : 1138549-36-6  
**Molecular Formula** : C<sub>27</sub>H<sub>27</sub>N<sub>7</sub>O<sub>2</sub>S  
**Molecular Weight** :  
**Target** : DNA/RNA Synthesis  
**Solubility** : DMSO: < 5.3 mg/mL



## Biological Activity

Pidnarulex (CX-5461) is the first potent, selective, orally bioavailable inhibitor of **RNA polymerase I**, selectively inhibits rRNA synthesis in HCT-116 cells with IC<sub>50</sub> of 142 nM, 200-fold selectivity over Pol II.

Pidnarulex (CX-5461) inhibits the initiation stage of rRNA synthesis and induces both senescence and autophagy, but not apoptosis, through a p53-independent process in solid tumor cell lines.

Pidnarulex (CX-5461) demonstrates in vivo antitumor activity against human solid tumors in murine xenograft models.

## References

Haddach M, et al. *ACS Med Chem Lett.* 2012 May 8;3(7):602-6.

Drygin D, et al. *Cancer Res.* 2011 Feb 15;71(4):1418-30.

Bywater MJ, et al. *Cancer Cell.* 2012 Jul 10;22(1):51-65.

Achiron A, et al. *J Neuroimmunol.* 2013 Oct 15;263(1-2):91-7.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com